Exemestane therapy after 2 to 3 years of tamoxifen therapy improved survival compared with 5 years of tamoxifen therapy alone

被引：0
|
作者：
Coombes, RC
Hall, E
Gibson, LJ
机构：
来源：
ANNALS OF INTERNAL MEDICINE | 2005年 / 143卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：824 / 824
页数：1
相关论文
共 50 条
  • [1] Adjuvant exemestane therapy after 5 years of tamoxifen: Rationale for the NSABP B-33 trial
    Mamounas, EP
    ONCOLOGY-NEW YORK, 2001, 15 (05): : 35 - 39
  • [2] Characteristics of recurrence after completing adjuvant tamoxifen therapy for 5 years
    Lee, Eunshin
    Lee, Han-Byoel
    Kang, Young Joon
    Kim, Yun-Gyoung
    Yoo, Tae-kyung
    Kim, Jongjin
    Kim, Min Kyoon
    Moon, Hyeong-Gon
    Noh, Dong-Young
    Han, Wonshik
    CANCER RESEARCH, 2015, 75
  • [3] Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
    Coombes, R. C.
    Kilburn, L. S.
    Snowdon, C. F.
    Paridaens, R.
    Coleman, R. E.
    Jones, S. E.
    Jassem, J.
    Van de Velde, C. J. H.
    Delozier, T.
    Alvarez, I.
    Del Mastro, L.
    Ortmann, O.
    Diedrich, K.
    Coates, A. S.
    Bajetta, E.
    Holmberg, S. B.
    Dodwell, D.
    Mickiewicz, E.
    Andersen, J.
    Lonning, P. E.
    Cocconi, G.
    Forbes, J.
    Castiglione, M.
    Stuart, N.
    Stewart, A.
    Fallowfield, L. J.
    Bertelli, G.
    Hall, E.
    Bogle, R. G.
    Carpentieri, M.
    Colajori, E.
    Subar, M.
    Ireland, E.
    Bliss, J. M.
    LANCET, 2007, 369 (9561): : 559 - 570
  • [4] Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2–3 years treatment with tamoxifen in Sweden
    Jonas Lundkvist
    Nils Wilking
    Stig Holmberg
    Linus Jönsson
    Breast Cancer Research and Treatment, 2007, 102 : 289 - 299
  • [5] Exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): results of NSABP B-33
    Geyer, C. E.
    Mamounas, E.
    Jeong, J. -H.
    Wickerham, L.
    Ganz, P.
    Hutchins, L.
    Eisen, A.
    Ingle, J.
    Costantino, J.
    Wolmark, N.
    BREAST, 2007, 16 : S46 - S46
  • [6] Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 152 - 152
  • [7] Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden
    Lundkvist, Jonas
    Wilking, Nils
    Holmberg, Stig
    Jonsson, Linus
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 102 (03) : 289 - 299
  • [8] Adjuvant Therapy with Tamoxifen Better 10 than 5 Years?
    Bangemann, N.
    ONKOLOGE, 2013, 19 (04): : 316 - 318
  • [9] A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
    Coombes, RC
    Hall, E
    Gibson, LJ
    Paridaens, R
    Jassem, J
    Delozier, T
    Jones, SE
    Alvarez, I
    Bertelli, G
    Ortmann, O
    Coates, AS
    Bajetta, E
    Dodwell, D
    Coleman, RE
    Fallowfield, LJ
    Mickiewicz, E
    Andersen, J
    Lonning, PE
    Cocconi, G
    Stewart, A
    Stuart, N
    Snowdon, CF
    Carpentieri, M
    Massimini, G
    Bliss, JM
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11): : 1081 - 1092
  • [10] Survival benefit of switching to anastrozole after 2 years' treatment with tamoxifen versus continued tamoxifen therapy: The ARNO 95 study.
    Kaufmann, M.
    Jonat, W.
    Hilfrich, J.
    Eidtmann, H.
    Gademann, G.
    Zuna, I.
    Von Minckwitz, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 14S - 14S
12345